Lenvatinib: all 359 studies that test it
Page 4 of 4. Open to participants first (137), then studies with results posted, then the rest; newest registration first within each.
- TACE Combined With Lenvatinib for Unresectable Hepatocellular CarcinomaStatus unknownNCT04490694Phase 2
- Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial CarcinomaStatus unknownNCT04444193Not applicable
- A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaCompletedNCT04444167Phase 1/2
- Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Phase 1/2
- Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Active, not recruitingNCT04427293Phase 1
- Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Not applicable
- Lenvatinib Combined Toripalimab in Advanced Hepatocellular CarcinomaStatus unknownNCT04368078Phase 2
- Lenvatinib in Locally Advanced Invasive Thyroid CancerCompletedNCT04321954Phase 2
- A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCCCompletedNCT04297254Phase 4
- Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsActive, not recruitingNCT04287829Phase 2
- Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCCStatus unknownNCT04241523Phase 2
- Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular CarcinomaStatus unknownNCT04227808Phase 2
- Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract CancersStatus unknownNCT04211168Phase 2
- Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 2
- A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III MelanomaActive, not recruitingNCT04207086Phase 2
- Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib FailureCompletedNCT04193553Phase 2
- Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2
- Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisStatus unknownNCT04170179Phase 2
- Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular CarcinomaStatus unknownNCT04168944Phase 2/3
- Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTTStatus unknownNCT04127396Phase 4
- The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.Status unknownNCT04053972Phase 3
- HAIC Plus Lenvatinib and Toripalimab for Advanced HCCCompletedNCT04044313Phase 2
- Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular CarcinomaStatus unknownNCT04042805Phase 2
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid TumorsActive, not recruitingNCT03950609Phase 2
- Phase II of Lenvatinib Plus Toripalimab for Advanced HCCWithdrawnNCT03919383Phase 2
- Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary TumorsCompletedNCT03895970Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular CarcinomaCompletedNCT03841201Phase 2
- Lenvatinib for Unresectable Intrahepatic CholangiocarcinomaWithdrawnNCT03801499Phase 2
- Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03791918Phase 3
- Lenvatinib Plus PD-1 Antibody for Unresectable ICCSuspendedNCT03779100Phase 2
- Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03775707Phase 2
- HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCCStatus unknownNCT03775395Phase 3
- Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCCWithdrawnNCT03746249Phase 2
- Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid CarcinomasStatus unknownNCT03732495Phase 2
- A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid CancerCompletedNCT03573960Phase 4
- Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)CompletedNCT03324373Phase 1
- Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal MelanomaActive, not recruitingNCT03313206Phase 2
- Phase II Study of Single Agent LenvatinibStatus unknownNCT03168074Phase 2
- UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib AloneSuspendedNCT03139747Phase 2
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid TumorCompletedNCT03009292Phase 1
- Lenvatinib in Second Line Endometrial CarcinomaWithdrawnNCT03005015Phase 2
- A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaCompletedNCT02966093Phase 3
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Phase 1
- Capecitabine and Lenvatinib With External Radiation in Rectal AdenocarcinomaCompletedNCT02935309Phase 1
- Lenvatinib and Capecitabine in Patients With Advanced MalignanciesWithdrawnNCT02915172Phase 1
- Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14CompletedNCT02860936Phase 2
- Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR SignalingWithdrawnNCT02846766Phase 2
- Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian CancerCompletedNCT02788708Phase 1
- Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaActive, not recruitingNCT02780310Phase 2
- Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid CancerCompletedNCT02726503Phase 2
- Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicable
- Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast CancerActive, not recruitingNCT02562118Phase 1/2
- A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)CompletedNCT02421042Phase 1
- A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy VolunteersCompletedNCT02199392Phase 1
- A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy SubjectsCompletedNCT02199379Phase 1
- A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc IntervalCompletedNCT01525394Phase 1
- E7080 Food Effect Study in Healthy SubjectsCompletedNCT01240408Phase 1
- A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic MelanomaCompletedNCT00121680Phase 1